nach oben

American Journal of Cardiovascular Drugs

Erschienen in:

31.07.2023 | Review Article

Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells

verfasst von: Yilin Xiong, Yan Wang, Tao Yang, Yunmei Luo, Shangfu Xu, Lisheng Li

Erschienen in: American Journal of Cardiovascular Drugs | Ausgabe 5/2023

Einloggen, um Zugang zu erhalten

Abstract

Vascular smooth muscle cells (VSMCs) proliferation is a critical event that contributes to the pathogenesis of vascular remodeling such as hypertension, restenosis, and pulmonary hypertension. Increasing evidences have revealed that VSMCs proliferation is associated with the activation of receptor tyrosine kinases (RTKs) by their ligands, including the insulin-like growth factor receptor (IGFR), fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR). Moreover, some receptor tyrosinase inhibitors (TKIs) have been found and can prevent VSMCs proliferation to attenuate vascular remodeling. Therefore, this review will describe recent research progress on the role of RTKs and their inhibitors in controlling VSMCs proliferation, which helps to better understand the function of VSMCs proliferation in cardiovascular events and is beneficial for the prevention and treatment of vascular disease.

Brown IAM, Diederich L, Good ME, DeLalio LJ, Murphy SA, Cortese-Krott MM, et al. Vascular smooth muscle remodeling in conductive and resistance arteries in hypertension. Arterioscler Thromb Vasc Biol. 2018;38(9):1969–85. https://doi.org/10.1161/atvbaha.118.311229.CrossRefPubMedPubMedCentral

Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner A, et al. Vascular smooth muscle contraction in hypertension. Cardiovasc Res. 2018;114(4):529–39. https://doi.org/10.1093/cvr/cvy023.CrossRefPubMedPubMedCentral

Ashraf JV, Al Haj Zen A. Role of vascular smooth muscle cell phenotype switching in arteriogenesis. Int J Mol Sci. 2021;22:19. https://doi.org/10.3390/ijms221910585.CrossRef

Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res. 2018;114(4):540–50. https://doi.org/10.1093/cvr/cvy022.CrossRefPubMedPubMedCentral

Worssam MD, Jørgensen HF. Mechanisms of vascular smooth muscle cell investment and phenotypic diversification in vascular diseases. Biochem Soc Trans. 2021;49(5):2101–11. https://doi.org/10.1042/bst20210138.CrossRefPubMedPubMedCentral

Zhang MJ, Zhou Y, Chen L, Wang YQ, Wang X, Pi Y, et al. An overview of potential molecular mechanisms involved in VSMC phenotypic modulation. Histochem Cell Biol. 2016;145(2):119–30. https://doi.org/10.1007/s00418-015-1386-3.CrossRefPubMed

Wang G, Jacquet L, Karamariti E, Xu Q. Origin and differentiation of vascular smooth muscle cells. J Physiol. 2015;593(14):3013–30. https://doi.org/10.1113/jp270033.CrossRefPubMedPubMedCentral

Li MX, Jiang DQ, Wang Y, Chen QZ, Ma YJ, Yu SS, et al. Signal mechanisms of vascular remodeling in the development of pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2016;67(2):182–90. https://doi.org/10.1097/fjc.0000000000000328.CrossRefPubMed

Batchu SN, Korshunov VA. Novel tyrosine kinase signaling pathways: implications in vascular remodeling. Curr Opin Nephrol Hypertens. 2012;21(2):122–7. https://doi.org/10.1097/MNH.0b013e3283503ce9.CrossRefPubMedPubMedCentral

10.

Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades. Cold Spring Harb Perspect Biol. 2014;6:3. https://doi.org/10.1101/cshperspect.a008912.CrossRef

11.

Trenker R, Jura N. Receptor tyrosine kinase activation: From the ligand perspective. Curr Opin Cell Biol. 2020;63:174–85. https://doi.org/10.1016/j.ceb.2020.01.016.CrossRefPubMedPubMedCentral

12.

Lam I, Pickering CM, Mac GF. Context-dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches. Wiley Interdiscip Rev Syst Biol Med. 2019;11(2): e1437. https://doi.org/10.1002/wsbm.1437.CrossRefPubMed

13.

Huang H. Proteolytic cleavage of receptor tyrosine kinases. Biomolecules. 2021. https://doi.org/10.3390/biom11050660.CrossRefPubMedPubMedCentral

14.

Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19113491.CrossRefPubMedPubMedCentral

15.

Chitturi KR, Burns EA, Muhsen IN, Anand K, Trachtenberg BH. Cardiovascular risks with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and monoclonal antibody therapy. Curr Oncol Rep. 2022;24(4):475–91. https://doi.org/10.1007/s11912-022-01215-1.CrossRefPubMed

16.

Shao W, Li X, Peng J, Fan S, Liang M, Huang K. Apatinib attenuates phenotypic switching of arterial smooth muscle cells in vascular remodelling by targeting the PDGF Receptor-β. J Cell Mol Med. 2020;24(17):10128–39. https://doi.org/10.1111/jcmm.15623.CrossRefPubMedPubMedCentral

17.

Kurakula K, Smolders V, Tura-Ceide O, Jukema JW, Quax PHA, Goumans MJ. Endothelial dysfunction in pulmonary hypertension: Cause or consequence? Biomedicines. 2021. https://doi.org/10.3390/biomedicines9010057.CrossRefPubMedPubMedCentral

18.

Chen B, Jin Y, Pool CM, Liu Y, Nelin LD. Hypoxic pulmonary endothelial cells release epidermal growth factor leading to vascular smooth muscle cell arginase-2 expression and proliferation. Physiol Rep. 2022;10(11): e15342. https://doi.org/10.14814/phy2.15342.CrossRefPubMedPubMedCentral

19.

Schreier B, Gekle M, Grossmann C. Role of epidermal growth factor receptor in vascular structure and function. Curr Opin Nephrol Hypertens. 2014;23(2):113–21. https://doi.org/10.1097/01.mnh.0000441152.62943.29.CrossRefPubMed

20.

Sun Y, Xiao Y, Sun H, Zhao Z, Zhu J, Zhang L, et al. miR-27a regulates vascular remodeling by targeting endothelial cells’ apoptosis and interaction with vascular smooth muscle cells in aortic dissection. Theranostics. 2019;9(25):7961–75. https://doi.org/10.7150/thno.35737.CrossRefPubMedPubMedCentral

21.

Qiu J, Zheng Y, Hu J, Liao D, Gregersen H, Deng X, et al. Biomechanical regulation of vascular smooth muscle cell functions: from in vitro to in vivo understanding. J R Soc Interface. 2014;11(90):20130852. https://doi.org/10.1098/rsif.2013.0852.CrossRefPubMedPubMedCentral

22.

Mammoto A, Hendee K, Muyleart M, Mammoto T. Endothelial Twist1-PDGFB signaling mediates hypoxia-induced proliferation and migration of αSMA-positive cells. Sci Rep. 2020;10(1):7563. https://doi.org/10.1038/s41598-020-64298-5.CrossRefPubMedPubMedCentral

23.

Chu F, Wang M, Ma H, Zhu J. Simvastatin modulates interaction between vascular smooth muscle cell/macrophage and TNF-α-activated endothelial cell. J Cardiovasc Pharmacol. 2018;71(5):268–74. https://doi.org/10.1097/fjc.0000000000000567.CrossRefPubMed

24.

Cucina A, Borrelli V, Randone B, Coluccia P, Sapienza P, Cavallaro A. Vascular endothelial growth factor increases the migration and proliferation of smooth muscle cells through the mediation of growth factors released by endothelial cells. J Surg Res. 2003;109(1):16–23. https://doi.org/10.1016/s0022-4804(02)00042-2.CrossRefPubMed

25.

de la Cuesta F, Passalacqua I, Rodor J, Bhushan R, Denby L, Baker AH. Extracellular vesicle cross-talk between pulmonary artery smooth muscle cells and endothelium during excessive TGF-β signalling: implications for PAH vascular remodelling. Cell Commun Signal. 2019;17(1):143. https://doi.org/10.1186/s12964-019-0449-9.CrossRefPubMedPubMedCentral

26.

Simons M, Eichmann A. Molecular controls of arterial morphogenesis. Circ Res. 2015;116(10):1712–24. https://doi.org/10.1161/circresaha.116.302953.CrossRefPubMedPubMedCentral

27.

Higashi Y, Gautam S, Delafontaine P, Sukhanov S. IGF-1 and cardiovascular disease. Growth Horm IGF Res. 2019;45:6–16. https://doi.org/10.1016/j.ghir.2019.01.002.CrossRefPubMed

28.

Lin X, Shan SK, Xu F, Zhong JY, Wu F, Duan JY, et al. The crosstalk between endothelial cells and vascular smooth muscle cells aggravates high phosphorus-induced arterial calcification. Cell Death Dis. 2022;13(7):650. https://doi.org/10.1038/s41419-022-05064-5.CrossRefPubMedPubMedCentral

29.

Osher E, Macaulay VM. Therapeutic targeting of the IGF axis. Cells. 2019. https://doi.org/10.3390/cells8080895.CrossRefPubMedPubMedCentral

30.

Xu S, Bala S, Bendeck MP. Discoidin domain receptor 1 deficiency in vascular smooth muscle cells leads to mislocalisation of N-cadherin contacts. Biol Open. 2019. https://doi.org/10.1242/bio.041913.CrossRefPubMedPubMedCentral

31.

Chen SC, Wang BW, Wang DL, Shyu KG. Hypoxia induces discoidin domain receptor-2 expression via the p38 pathway in vascular smooth muscle cells to increase their migration. Biochem Biophys Res Commun. 2008;374(4):662–7. https://doi.org/10.1016/j.bbrc.2008.07.092.CrossRefPubMed

32.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–5. https://doi.org/10.1126/science.6823562.CrossRefPubMed

33.

Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell. 2019;176(6):1248–64. https://doi.org/10.1016/j.cell.2019.01.021.CrossRefPubMedPubMedCentral

34.

Lv YX, Zhong S, Tang H, Luo B, Chen SJ, Chen L, et al. VEGF-A and VEGF-B coordinate the arteriogenesis to repair the infarcted heart with vagus nerve stimulation. Cell Physiol Biochem. 2018;48(2):433–49. https://doi.org/10.1159/000491775.CrossRefPubMed

35.

Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313(8):1561–74. https://doi.org/10.1016/j.yexcr.2007.02.020.CrossRefPubMed

36.

Schlich R, Willems M, Greulich S, Ruppe F, Knoefel WT, Ouwens DM, et al. VEGF in the crosstalk between human adipocytes and smooth muscle cells: depot-specific release from visceral and perivascular adipose tissue. Mediators Inflamm. 2013. https://doi.org/10.1155/2013/982458.CrossRefPubMedPubMedCentral

37.

Chang HJ, Park JS, Kim MH, Hong MH, Kim KM, Kim SM, et al. Extracellular signal-regulated kinases and AP-1 mediate the up-regulation of vascular endothelial growth factor by PDGF in human vascular smooth muscle cells. Int J Oncol. 2006;28(1):135–41.PubMed

38.

Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol. 1992;151(1):81–93. https://doi.org/10.1002/jcp.1041510113.CrossRefPubMed

39.

Li D, Zhang C, Song F, Lubenec I, Tian Y, Song QH. VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res. 2009;77(2):134–42. https://doi.org/10.1016/j.mvr.2008.09.007.CrossRefPubMed

40.

Parenti A, Bellik L, Brogelli L, Filippi S, Ledda F. Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004;286(5):H1978–84. https://doi.org/10.1152/ajpheart.00414.2003.CrossRefPubMed

41.

Sini P, Wyder L, Schnell C, O’Reilly T, Littlewood A, Brandt R, et al. The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade. Clin Cancer Res. 2005;11(12):4521–32. https://doi.org/10.1158/1078-0432.Ccr-04-1954.CrossRefPubMed

42.

Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67.PubMed

43.

Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res. 2018;136:97–107. https://doi.org/10.1016/j.phrs.2018.08.023.CrossRefPubMed

44.

Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745–70. https://doi.org/10.1007/s00018-019-03351-7.CrossRefPubMed

45.

Liu JR, Wang HF, Yu DF, Chen XY, He SY. Modulation of binding to vascular endothelial growth factor and receptor by heparin derived oligosaccharide. Carbohydr Polym. 2017;174:558–64. https://doi.org/10.1016/j.carbpol.2017.06.127.CrossRefPubMed

46.

Liao XH, Xiang Y, Li H, Zheng L, Xu Y, Xi YuC, et al. VEGF-A stimulates stat3 activity via nitrosylation of myocardin to regulate the expression of vascular smooth muscle cell differentiation markers. Sci Rep. 2017;7(1):2660. https://doi.org/10.1038/s41598-017-02907-6.CrossRefPubMedPubMedCentral

47.

Camarda N, Travers R, Yang VK, London C, Jaffe IZ. VEGF Receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications. Curr Oncol Rep. 2022;24(4):463–74. https://doi.org/10.1007/s11912-022-01224-0.CrossRefPubMedPubMedCentral

48.

Zhu WH, MacIntyre A, Nicosia RF. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. Am J Pathol. 2002;161(3):823–30. https://doi.org/10.1016/s0002-9440(10)64242-3.CrossRefPubMedPubMedCentral

49.

Breier G. Functions of the VEGF/VEGF receptor system in the vascular system. Semin Thromb Hemost. 2000;26(5):553–9. https://doi.org/10.1055/s-2000-13212.CrossRefPubMed

50.

Adeoye OO, Butler SM, Hubbell MC, Semotiuk A, Williams JM, Pearce WJ. Contribution of increased VEGF receptors to hypoxic changes in fetal ovine carotid artery contractile proteins. Am J Physiol Cell Physiol. 2013;304(7):C656–65. https://doi.org/10.1152/ajpcell.00110.2012.CrossRefPubMedPubMedCentral

51.

Yu J, Rupasinghe C, Wilson JL, Taylor L, Rahimi N, Mierke D, et al. Targeting receptor tyrosine kinases and their downstream signaling with cell-penetrating peptides in human pulmonary artery smooth muscle and endothelial cells. Chem Biol Drug Des. 2015;85(5):586–97. https://doi.org/10.1111/cbdd.12446.CrossRefPubMed

52.

Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2):e1–8. https://doi.org/10.1161/hypertensionaha.117.10271.CrossRefPubMed

53.

Ylä-Herttuala S, Baker AH. Cardiovascular gene therapy: Past, present, and future. Mol Ther. 2017;25(5):1095–106. https://doi.org/10.1016/j.ymthe.2017.03.027.CrossRefPubMedPubMedCentral

54.

Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19051308.CrossRefPubMedPubMedCentral

55.

Shin M, Kang HS, Park JH, Bae JH, Song DK, Im SS. Recent insights into insulin-like growth factor binding protein 2 transcriptional regulation. Endocrinol Metab (Seoul). 2017;32(1):11–7. https://doi.org/10.3803/EnM.2017.32.1.11.CrossRefPubMedPubMedCentral

56.

Ren J, Anversa P. The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome. Biochem Pharmacol. 2015;93(4):409–17. https://doi.org/10.1016/j.bcp.2014.12.006.CrossRefPubMed

57.

Chisalita SI, Johansson GS, Liefvendahl E, Bäck K, Arnqvist HJ. Human aortic smooth muscle cells are insulin resistant at the receptor level but sensitive to IGF1 and IGF2. J Mol Endocrinol. 2009;43(6):231–9. https://doi.org/10.1677/jme-09-0021.CrossRefPubMed

58.

Beneit N, Fernández-García CE, Martín-Ventura JL, Perdomo L, Escribano Ó, Michel JB, et al. Expression of insulin receptor (IR) A and B isoforms, IGF-IR, and IR/IGF-IR hybrid receptors in vascular smooth muscle cells and their role in cell migration in atherosclerosis. Cardiovasc Diabetol. 2016;15(1):161. https://doi.org/10.1186/s12933-016-0477-3.CrossRefPubMedPubMedCentral

59.

Liu G, Hitomi H, Hosomi N, Lei B, Nakano D, Deguchi K, et al. Mechanical stretch augments insulin-induced vascular smooth muscle cell proliferation by insulin-like growth factor-1 receptor. Exp Cell Res. 2011;317(17):2420–8. https://doi.org/10.1016/j.yexcr.2011.07.016.CrossRefPubMed

60.

Zaina S, Pettersson L, Ahrén B, Brånén L, Hassan AB, Lindholm M, et al. Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. J Biol Chem. 2002;277(6):4505–11. https://doi.org/10.1074/jbc.M108061200.CrossRefPubMed

61.

Wu X, Zheng X, Cheng J, Zhang K, Ma C. LncRNA TUG1 regulates proliferation and apoptosis by regulating miR-148b/IGF2 axis in ox-LDL-stimulated VSMC and HUVEC. Life Sci. 2020;243: 117287. https://doi.org/10.1016/j.lfs.2020.117287.CrossRefPubMed

62.

Yang N, Dong B, Song Y, Li Y, Kou L, Yang J, et al. Downregulation of miR-637 promotes vascular smooth muscle cell proliferation and migration via regulation of insulin-like growth factor-2. Cell Mol Biol Lett. 2020;25:30. https://doi.org/10.1186/s11658-020-00222-z.CrossRefPubMedPubMedCentral

63.

Shuang T, Fu M, Yang G, Wu L, Wang R. The interaction of IGF-1/IGF-1R and hydrogen sulfide on the proliferation of mouse primary vascular smooth muscle cells. Biochem Pharmacol. 2018;149:143–52. https://doi.org/10.1016/j.bcp.2017.12.009.CrossRefPubMed

64.

Shai SY, Sukhanov S, Higashi Y, Vaughn C, Kelly J, Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol. 2010;30(10):1916–24. https://doi.org/10.1161/atvbaha.110.210831.CrossRefPubMedPubMedCentral

65.

Sukhanov S, Higashi Y, Shai SY, Snarski P, Danchuk S, D’Ambra V, et al. SM22α (smooth muscle protein 22-α) promoter-driven IGF1R (insulin-like growth factor 1 receptor) deficiency promotes atherosclerosis. Arterioscler Thromb Vasc Biol. 2018;38(10):2306–17. https://doi.org/10.1161/atvbaha.118.311134.CrossRefPubMedPubMedCentral

66.

Jiang W, Block ME, Boosani CS. Short communication: TNF-α and IGF-1 regulates epigenetic mechanisms of HDAC2 and HDAC10. PLoS ONE. 2022;17(2): e0263190. https://doi.org/10.1371/journal.pone.0263190.CrossRefPubMedPubMedCentral

67.

Gao S, Wassler M, Zhang L, Li Y, Wang J, Zhang Y, et al. MicroRNA-133a regulates insulin-like growth factor-1 receptor expression and vascular smooth muscle cell proliferation in murine atherosclerosis. Atherosclerosis. 2014;232(1):171–9. https://doi.org/10.1016/j.atherosclerosis.2013.11.029.CrossRefPubMed

68.

von der Thüsen JH, Borensztajn KS, Moimas S, van Heiningen S, Teeling P, van Berkel TJ, et al. IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am J Pathol. 2011;178(2):924–34. https://doi.org/10.1016/j.ajpath.2010.10.007.CrossRefPubMedPubMedCentral

69.

Macvanin M, Gluvic Z, Radovanovic J, Essack M, Gao X, Isenovic ER. New insights on the cardiovascular effects of IGF-1. Front Endocrinol (Lausanne). 2023;14:1142644. https://doi.org/10.3389/fendo.2023.1142644.CrossRefPubMedPubMedCentral

70.

Gusscott S, Jenkins CE, Lam SH, Giambra V, Pollak M, Weng AP. IGF1R derived PI3K/AKT signaling maintains growth in a subset of human t-cell acute lymphoblastic leukemias. PLoS ONE. 2016;11(8): e0161158. https://doi.org/10.1371/journal.pone.0161158.CrossRefPubMedPubMedCentral

71.

Abbas A, Imrie H, Viswambharan H, Sukumar P, Rajwani A, Cubbon RM, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes. 2011;60(8):2169–78. https://doi.org/10.2337/db11-0197.CrossRefPubMedPubMedCentral

72.

Li Q, Fu J, Xia Y, Qi W, Ishikado A, Park K, et al. Homozygous receptors for insulin and not IGF-1 accelerate intimal hyperplasia in insulin resistance and diabetes. Nat Commun. 2019;10(1):4427. https://doi.org/10.1038/s41467-019-12368-2.CrossRefPubMedPubMedCentral

73.

Guérit E, Arts F, Dachy G, Boulouadnine B, Demoulin JB. PDGF receptor mutations in human diseases. Cell Mol Life Sci. 2021;78(8):3867–81. https://doi.org/10.1007/s00018-020-03753-y.CrossRefPubMed

74.

Sachinidis A, Locher R, Vetter W, Tatje D, Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J Biol Chem. 1990;265(18):10238–43.CrossRefPubMed

75.

Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75–88. https://doi.org/10.1016/j.mam.2017.11.007.CrossRefPubMed

76.

Donovan J, Abraham D, Norman J. Platelet-derived growth factor signaling in mesenchymal cells. Front Biosci (Landmark Ed). 2013;18(1):106–19. https://doi.org/10.2741/4090.CrossRefPubMed

77.

Ostman A, Thyberg J, Westermark B, Heldin CH. PDGF-AA and PDGF-BB biosynthesis: proprotein processing in the Golgi complex and lysosomal degradation of PDGF-BB retained intracellularly. J Cell Biol. 1992;118(3):509–19. https://doi.org/10.1083/jcb.118.3.509.CrossRefPubMed

78.

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183–90. https://doi.org/10.1161/01.Hyp.0000069700.62727.C5.CrossRefPubMed

79.

Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int. 2006;69(10):1780–5. https://doi.org/10.1038/sj.ki.5000340.CrossRefPubMed

80.

Zhang D, Chen Y, Xie X, Liu J, Wang Q, Kong W, et al. Homocysteine activates vascular smooth muscle cells by DNA demethylation of platelet-derived growth factor in endothelial cells. J Mol Cell Cardiol. 2012;53(4):487–96. https://doi.org/10.1016/j.yjmcc.2012.07.010.CrossRefPubMed

81.

Hervouet E, Debien E, Campion L, Charbord J, Menanteau J, Vallette FM, et al. Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation. Clin Cancer Res. 2009;15(10):3519–29. https://doi.org/10.1158/1078-0432.Ccr-08-2062.CrossRefPubMed

82.

Shawer H, Norman K, Cheng CW, Foster R, Beech DJ, Bailey MA. ORAI1 Ca(2+) channel as a therapeutic target in pathological vascular remodelling. Front Cell Dev Biol. 2021;9: 653812. https://doi.org/10.3389/fcell.2021.653812.CrossRefPubMedPubMedCentral

83.

Pan S, Lin H, Luo H, Gao F, Meng L, Zhou C, et al. Folic acid inhibits dedifferentiation of PDGF-BB-induced vascular smooth muscle cells by suppressing mTOR/P70S6K signaling. Am J Transl Res. 2017;9(3):1307–16.PubMedPubMedCentral

84.

Shin SS, Ko MC, Noh DH, Hwang B, Park Y, Park SL, et al. Morin inhibits PDGF-induced proliferation, migration, and invasion of vascular smooth muscle cells via modulating p27KIP1, AKT, and MMP-9 activities. Gen Physiol Biophys. 2018;37(6):633–45. https://doi.org/10.4149/gpb_2018028.CrossRefPubMed

85.

Zhu ZR, He Q, Wu WB, Chang GQ, Yao C, Zhao Y, et al. MiR-140-3p is involved in in-stent restenosis by targeting C-Myb and BCL-2 in peripheral artery disease. J Atheroscler Thromb. 2018;25(11):1168–81. https://doi.org/10.5551/jat.44024.CrossRefPubMedPubMedCentral

86.

Lu QB, Wan MY, Wang PY, Zhang CX, Xu DY, Liao X, et al. Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFκB/mTOR/P70S6K signaling cascade. Redox Biol. 2018;14:656–68. https://doi.org/10.1016/j.redox.2017.11.012.CrossRefPubMed

87.

Wågsäter D, Zhu C, Björck HM, Eriksson P. Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis. 2009;202(2):415–23. https://doi.org/10.1016/j.atherosclerosis.2008.04.050.CrossRefPubMed

88.

Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15(4):237–54. https://doi.org/10.1016/j.cytogfr.2004.03.004.CrossRefPubMed

89.

Xiang Y, Li L, Xia S, Lv J, Li X. Cullin3 (CUL3) suppresses proliferation, migration and phenotypic transformation of PDGF-BB-stimulated vascular smooth muscle cells and mitigates inflammatory response by repressing Hedgehog signaling pathway. Bioengineered. 2021;12(2):9463–72. https://doi.org/10.1080/21655979.2021.1995572.CrossRefPubMedPubMedCentral

90.

Wu Q, Chen Y, Wang Z, Cai X, Che Y, Zheng S, et al. Mangiferin inhibits PDGF-BB-induced proliferation and migration of rat vascular smooth muscle cells and alleviates neointimal formation in mice through the AMPK/Drp1 axis. Oxid Med Cell Longev. 2021;2021:3119953. https://doi.org/10.1155/2021/3119953.CrossRefPubMedPubMedCentral

91.

Tang C, Wang D, Luo E, Yan G, Liu B, Hou J, et al. Activation of inward rectifier K(+) channel 2.1 by pdgf-bb in rat vascular smooth muscle cells through protein kinase A. Biomed Res Int. 2020;2020:4370832. https://doi.org/10.1155/2020/4370832.CrossRefPubMedPubMedCentral

92.

Thiel WH, Esposito CL, Dickey DD, Dassie JP, Long ME, Adam J, et al. Smooth muscle cell-targeted RNA aptamer inhibits neointimal formation. Mol Ther. 2016;24(4):779–87. https://doi.org/10.1038/mt.2015.235.CrossRefPubMedPubMedCentral

93.

Chen PH, Unger V, He X. Structure of full-length human PDGFRβ bound to its activating ligand PDGF-B as determined by negative-stain electron microscopy. J Mol Biol. 2015;427(24):3921–34. https://doi.org/10.1016/j.jmb.2015.10.003.CrossRefPubMedPubMedCentral

94.

Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis. Mol Aspects Med. 2018;62:44–62. https://doi.org/10.1016/j.mam.2017.11.008.CrossRefPubMed

95.

Inui H, Kitami Y, Tani M, Kondo T, Inagami T. Differences in signal transduction between platelet-derived growth factor (PDGF) alpha and beta receptors in vascular smooth muscle cells. PDGF-BB is a potent mitogen, but PDGF-AA promotes only protein synthesis without activation of DNA synthesis. J Biol Chem. 1994;269(48):30546–52.CrossRefPubMed

96.

Heldin CH, Lennartsson J. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb Perspect Biol. 2013;5(8): a009100. https://doi.org/10.1101/cshperspect.a009100.CrossRefPubMedPubMedCentral

97.

Armelin HA. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci U S A. 1973;70(9):2702–6. https://doi.org/10.1073/pnas.70.9.2702.CrossRefPubMedPubMedCentral

98.

Kuo CH, Sung MC, Chen PK, Chang BI, Lee FT, Cho CF, et al. FGFR1 mediates recombinant thrombomodulin domain-induced angiogenesis. Cardiovasc Res. 2015;105(1):107–17. https://doi.org/10.1093/cvr/cvu239.CrossRefPubMed

99.

Billings PC, Pacifici M. Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries. Connect Tissue Res. 2015;56(4):272–80. https://doi.org/10.3109/03008207.2015.1045066.CrossRefPubMedPubMedCentral

100.

Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res. 2010;106(6):1061–71. https://doi.org/10.1161/circresaha.109.206029.CrossRefPubMed

101.

Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001;81(3):999–1030. https://doi.org/10.1152/physrev.2001.81.3.999.CrossRefPubMed

102.

Ye G, Fu Q, Jiang L, Li Z. Vascular smooth muscle cells activate PI3K/Akt pathway to attenuate myocardial ischemia/reperfusion-induced apoptosis and autophagy by secreting bFGF. Biomed Pharmacother. 2018;107:1779–85. https://doi.org/10.1016/j.biopha.2018.05.113.CrossRefPubMed

103.

Tsutsumi T, Nagaoka T, Yoshida T, Wang L, Kuriyama S, Suzuki Y, et al. Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation. PLoS ONE. 2019;14(7): e0214697. https://doi.org/10.1371/journal.pone.0214697.CrossRefPubMedPubMedCentral

104.

Cucina A, Borrelli V, Lucarelli M, Sterpetti AV, Cavallaro A, Strom R, et al. Autocrine production of basic fibroblast growth factor translated from novel synthesized mRNA mediates thrombin-induced mitogenesis in smooth muscle cells. Cell Biochem Funct. 2002;20(1):39–46. https://doi.org/10.1002/cbf.938.CrossRefPubMed

105.

Tsuji-Tamura K, Tamura M. Basic fibroblast growth factor uniquely stimulates quiescent vascular smooth muscle cells and induces proliferation and dedifferentiation. FEBS Lett. 2022;596(13):1686–99. https://doi.org/10.1002/1873-3468.14345.CrossRefPubMed

106.

George SJ, Johnson JL, Smith MA, Jackson CL. Plasmin-mediated fibroblast growth factor-2 mobilisation supports smooth muscle cell proliferation in human saphenous vein. J Vasc Res. 2001;38(5):492–501. https://doi.org/10.1159/000051082.CrossRefPubMed

107.

Kurban G, Ishiwata T, Kudo M, Yokoyama M, Sugisaki Y, Naito Z. Expression of keratinocyte growth factor receptor (KGFR/FGFR2 IIIb) in human uterine cervical cancer. Oncol Rep. 2004;11(5):987–91.PubMed

108.

Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE. A protective role for FGF-23 in local defence against disrupted arterial wall integrity? Mol Cell Endocrinol. 2013;372(1–2):1–11. https://doi.org/10.1016/j.mce.2013.03.008.CrossRefPubMedPubMedCentral

109.

Batra J, Buttar RS, Kaur P, Kreimerman J, Melamed ML. FGF-23 and cardiovascular disease: review of literature. Curr Opin Endocrinol Diabetes Obes. 2016;23(6):423–9. https://doi.org/10.1097/med.0000000000000294.CrossRefPubMedPubMedCentral

110.

Wang YS, Wang HY, Liao YC, Tsai PC, Chen KC, Cheng HY, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 2012;95(4):517–26. https://doi.org/10.1093/cvr/cvs223.CrossRefPubMed

111.

Song SH, Kim K, Jo EK, Kim YW, Kwon JS, Bae SS, et al. Fibroblast growth factor 12 is a novel regulator of vascular smooth muscle cell plasticity and fate. Arterioscler Thromb Vasc Biol. 2016;36(9):1928–36. https://doi.org/10.1161/atvbaha.116.308017.CrossRefPubMed

112.

Chen PY, Simons M. Fibroblast growth factor-transforming growth factor beta dialogues, endothelial cell to mesenchymal transition, and atherosclerosis. Curr Opin Lipidol. 2018;29(5):397–403. https://doi.org/10.1097/mol.0000000000000542.CrossRefPubMedPubMedCentral

113.

Abud HE, Chan WH, Jardé T. Source and impact of the EGF family of ligands on intestinal stem cells. Front Cell Dev Biol. 2021;9: 685665. https://doi.org/10.3389/fcell.2021.685665.CrossRefPubMedPubMedCentral

114.

Zeng F, Harris RC. Epidermal growth factor, from gene organization to bedside. Semin Cell Dev Biol. 2014;28:2–11. https://doi.org/10.1016/j.semcdb.2014.01.011.CrossRefPubMed

115.

Schreier B, Schwerdt G, Heise C, Bethmann D, Rabe S, Mildenberger S, et al. Substance-specific importance of EGFR for vascular smooth muscle cells motility in primary culture. Biochim Biophys Acta. 2016;1863(7):1519–33. https://doi.org/10.1016/j.bbamcr.2016.03.017.CrossRefPubMed

116.

Makki N, Thiel KW, Miller FJ Jr. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci. 2013;14(10):20597–613. https://doi.org/10.3390/ijms141020597.CrossRefPubMedPubMedCentral

117.

Schreier B, Hünerberg M, Mildenberger S, Rabe S, Bethmann D, Wickenhauser C, et al. Deletion of the EGF receptor in vascular smooth muscle cells prevents chronic angiotensin II-induced arterial wall stiffening and media thickening. Acta Physiol. 2018. https://doi.org/10.1111/apha.12996.CrossRef

118.

Elliott KJ, Bourne AM, Takayanagi T, Takaguri A, Kobayashi T, Eguchi K, et al. ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells. J Mol Cell Cardiol. 2013;62:1–7. https://doi.org/10.1016/j.yjmcc.2013.05.005.CrossRefPubMedPubMedCentral

119.

Hsieh HL, Tung WH, Wu CY, Wang HH, Lin CC, Wang TS, et al. Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2009;29(10):1594–601. https://doi.org/10.1161/atvbaha.109.185801.CrossRefPubMed

120.

Shah BH, Catt KJ. A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol Sci. 2003;24(5):239–44. https://doi.org/10.1016/s0165-6147(03)00079-8.CrossRefPubMed

121.

Nolze A, Köhler C, Ruhs S, Quarch K, Strätz N, Gekle M, et al. Calcineurin (PPP3CB) regulates angiotensin II-dependent vascular remodelling by potentiating EGFR signalling in mice. Acta Physiol (Oxf). 2021;233(3): e13715. https://doi.org/10.1111/apha.13715.CrossRefPubMed

122.

Lachaud CC, López-Beas J, Soria B, Hmadcha A. EGF-induced adipose tissue mesothelial cells undergo functional vascular smooth muscle differentiation. Cell Death Dis. 2014;5(6): e1304. https://doi.org/10.1038/cddis.2014.271.CrossRefPubMedPubMedCentral

123.

Jhun H, Baek S, Kim J, Lee KP, Park HY, Park WH, et al. Effect of Korean Magnolia obovata extract on platelet-derived growth factor-induced vascular smooth muscle cells. Chin J Integr Med. 2020;26(9):677–82. https://doi.org/10.1007/s11655-019-3171-y.CrossRefPubMed

124.

Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW. Platelet-derived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc Med. 2006;16(1):25–8. https://doi.org/10.1016/j.tcm.2005.11.003.CrossRefPubMed

125.

Osman I, Dong K, Kang X, Yu L, Xu F, Ahmed ASI, et al. YAP1/TEAD1 upregulate platelet-derived growth factor receptor beta to promote vascular smooth muscle cell proliferation and neointima formation. J Mol Cell Cardiol. 2021;156:20–32. https://doi.org/10.1016/j.yjmcc.2021.03.005.CrossRefPubMedPubMedCentral

126.

Han JH, Park HS, Lee DH, Jo JH, Heo KS, Myung CS. Regulation of autophagy by controlling Erk1/2 and mTOR for platelet-derived growth factor-BB-mediated vascular smooth muscle cell phenotype shift. Life Sci. 2021;267: 118978. https://doi.org/10.1016/j.lfs.2020.118978.CrossRefPubMed

127.

Zhu N, Xiang Y, Zhao X, Cai C, Chen H, Jiang W, et al. Thymoquinone suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation, migration and neointimal formation. J Cell Mol Med. 2019;23(12):8482–92. https://doi.org/10.1111/jcmm.14738.CrossRefPubMedPubMedCentral

128.

Luo Y, Tang H, Zhang Z, Zhao R, Wang C, Hou W, et al. Pharmacological inhibition of epidermal growth factor receptor attenuates intracranial aneurysm formation by modulating the phenotype of vascular smooth muscle cells. CNS Neurosci Ther. 2022;28(1):64–76. https://doi.org/10.1111/cns.13735.CrossRefPubMed

129.

Willems-Widyastuti A, Vanaudenaerde BM, Vos R, Dilisen E, Verleden SE, De Vleeschauwer SI, et al. Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(MAPK) signaling in human airway smooth muscle cells. Cell Biochem Biophys. 2013;67(2):331–9. https://doi.org/10.1007/s12013-011-9331-0.CrossRefPubMed

130.

Smith GA, Fearnley GW, Harrison MA, Tomlinson DC, Wheatcroft SB, Ponnambalam S. Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. J Inherit Metab Dis. 2015;38(4):753–63. https://doi.org/10.1007/s10545-015-9838-4.CrossRefPubMed

131.

Chang Y, Li JY, Jayakumar T, Hung SH, Lee WC, Manubolu M, et al. Ketamine, a clinically used anesthetic, inhibits vascular smooth muscle cell proliferation via PP2A-activated PI3K/Akt/ERK inhibition. Int J Mol Sci. 2017. https://doi.org/10.3390/ijms18122545.CrossRefPubMedPubMedCentral

132.

Fiola-Masson E, Artigalas J, Campbell S, Claing A. Activation of the GTPase ARF6 regulates invasion of human vascular smooth muscle cells by stimulating MMP14 activity. Sci Rep. 2022;12(1):9532. https://doi.org/10.1038/s41598-022-13574-7.CrossRefPubMedPubMedCentral

133.

Chen Y, Chen Y, Jiang X, Shi M, Yang Z, Chen Z, et al. Vascular adventitial fibroblasts-derived FGF10 promotes vascular smooth muscle cells proliferation and migration in vitro and the neointima formation in vivo. J Inflamm Res. 2021;14:2207–23. https://doi.org/10.2147/jir.S305204.CrossRefPubMedPubMedCentral

134.

Cao H, Dronadula N, Rao GN. Thrombin induces expression of FGF-2 via activation of PI3K-Akt-Fra-1 signaling axis leading to DNA synthesis and motility in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2006;290(1):C172–82. https://doi.org/10.1152/ajpcell.00284.2005.CrossRefPubMed

135.

Zhu D, Mackenzie NC, Millan JL, Farquharson C, Macrae VE. Upregulation of IGF2 expression during vascular calcification. J Mol Endocrinol. 2014;52(2):77–85. https://doi.org/10.1530/jme-13-0136.CrossRefPubMedPubMedCentral

136.

Jiang R, Teng Y, Huang Y, Gu J, Ma L, Li M, et al. Preeclampsia serum-induced collagen I expression and intracellular calcium levels in arterial smooth muscle cells are mediated by the PLC-γ1 pathway. Exp Mol Med. 2014;46(9): e115. https://doi.org/10.1038/emm.2014.59.CrossRefPubMedPubMedCentral

137.

Kesavan R, Chandel S, Upadhyay S, Bendre R, Ganugula R, Potunuru UR, et al. Gentiana lutea exerts anti-atherosclerotic effects by preventing endothelial inflammation and smooth muscle cell migration. Nutr Metab Cardiovasc Dis. 2016;26(4):293–301. https://doi.org/10.1016/j.numecd.2015.12.016.CrossRefPubMed

138.

Choi BK, Cha BY, Yagyu T, Woo JT, Ojika M. Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet-derived growth factor (PDGF)-induced vascular smooth muscle cells. Bioorg Med Chem. 2013;21(7):1804–10. https://doi.org/10.1016/j.bmc.2013.01.039.CrossRefPubMed

139.

Song H, Xu J, Lv N, Zhang Y, Wu F, Li H, et al. Irisin reverses platelet derived growth factor-BB-induced vascular smooth muscle cells phenotype modulation through STAT3 signaling pathway. Biochem Biophys Res Commun. 2016;479(2):139–45. https://doi.org/10.1016/j.bbrc.2016.07.052.CrossRefPubMed

140.

Tong L, Qi G. Crocin prevents platelet-derived growth factor BB-induced vascular smooth muscle cells proliferation and phenotypic switch. Mol Med Rep. 2018;17(6):7595–602. https://doi.org/10.3892/mmr.2018.8854.CrossRefPubMedPubMedCentral

141.

McTigue MA, Wickersham JA, Pinko C, Showalter RE, Parast CV, Tempczyk-Russell A, et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. Structure. 1999;7(3):319–30. https://doi.org/10.1016/s0969-2126(99)80042-2.CrossRefPubMed

142.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, et al. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family. Mol Cancer Ther. 2011;10(5):861–73. https://doi.org/10.1158/1535-7163.Mct-10-0976.CrossRefPubMed

143.

Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, et al. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther. 2011;10(11):2157–67. https://doi.org/10.1158/1535-7163.Mct-11-0312.CrossRefPubMed

144.

Hacker TA, Griffin MO, Guttormsen B, Stoker S, Wolff MR. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. J Invasive Cardiol. 2007;19(6):269–74.PubMed

145.

Makiyama Y, Toba K, Kato K, Hirono S, Ozawa T, Saigawa T, et al. Imatinib mesilate inhibits neointimal hyperplasia via growth inhibition of vascular smooth muscle cells in a rat model of balloon injury. Tohoku J Exp Med. 2008;215(4):299–306. https://doi.org/10.1620/tjem.215.299.CrossRefPubMed

146.

Ishii S, Okamoto Y, Katsumata H, Egawa S, Yamanaka D, Fukushima M, et al. Sunitinib, a small-molecule receptor tyrosine kinase inhibitor, suppresses neointimal hyperplasia in balloon-injured rat carotid artery. J Cardiovasc Pharmacol Ther. 2013;18(4):359–66. https://doi.org/10.1177/1074248412472258.CrossRefPubMed

147.

Chen J, Dai M, Wang Y. Paeonol inhibits proliferation of vascular smooth muscle cells stimulated by high glucose via Ras-Raf-ERK1/2 signaling pathway in coculture model. Evid Based Complement Alternat Med. 2014;2014: 484269. https://doi.org/10.1155/2014/484269.CrossRefPubMedPubMedCentral

148.

Oak MH, Bedoui JE, Madeira SV, Chalupsky K, Schini-Kerth VB. Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK. Br J Pharmacol. 2006;149(3):283–90. https://doi.org/10.1038/sj.bjp.0706843.CrossRefPubMedPubMedCentral

149.

Ran F, Li W, Qin Y, Yu T, Liu Z, Zhou M, et al. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation. Oxid Med Cell Longev. 2021;2021:8321400. https://doi.org/10.1155/2021/8321400.CrossRefPubMedPubMedCentral

150.

Meng D, Shi X, Jiang BH, Fang J. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species. Free Radic Biol Med. 2007;42(11):1651–60. https://doi.org/10.1016/j.freeradbiomed.2007.01.037.CrossRefPubMed

151.

Wu YT, Bi YM, Tan ZB, Xie LP, Xu HL, Fan HJ, et al. Tanshinone I inhibits vascular smooth muscle cell proliferation by targeting insulin-like growth factor-1 receptor/phosphatidylinositol-3-kinase signaling pathway. Eur J Pharmacol. 2019;853:93–102. https://doi.org/10.1016/j.ejphar.2019.03.021.CrossRefPubMed

152.

Li M, Chiu JF, Gagne J, Fukagawa NK. Age-related differences in insulin-like growth factor-1 receptor signaling regulates Akt/FOXO3a and ERK/Fos pathways in vascular smooth muscle cells. J Cell Physiol. 2008;217(2):377–87. https://doi.org/10.1002/jcp.21507.CrossRefPubMedPubMedCentral

153.

Mallawaarachchi CM, Weissberg PL, Siow RC. Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs? Faseb j. 2006;20(10):1686–8. https://doi.org/10.1096/fj.05-5435fje.CrossRefPubMed

154.

Chhina MK, Nargues W, Grant GM, Nathan SD. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol. 2010;6(1):19–35. https://doi.org/10.2217/fca.09.54.CrossRefPubMed

155.

ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs. 2012;21(1):119–34. https://doi.org/10.1517/13543784.2012.632408.CrossRefPubMed

156.

Pankey EA, Thammasiboon S, Lasker GF, Baber S, Lasky JA, Kadowitz PJ. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat. Am J Physiol Heart Circ Physiol. 2013;305(9):H1288–96. https://doi.org/10.1152/ajpheart.00329.2013.CrossRefPubMedPubMedCentral

157.

Wu K, Tang H, Lin R, Carr SG, Wang Z, Babicheva A, et al. Endothelial platelet-derived growth factor-mediated activation of smooth muscle platelet-derived growth factor receptors in pulmonary arterial hypertension. Pulm Circ. 2020;10(3):2045894020948470. https://doi.org/10.1177/2045894020948470.CrossRefPubMedPubMedCentral

158.

Miyachi H, Tara S, Otsuru S, Yi T, Lee YU, Drews JD, et al. Imatinib attenuates neotissue formation during vascular remodeling in an arterial bioresorbable vascular graft. JVS Vasc Sci. 2020;1:57–67. https://doi.org/10.1016/j.jvssci.2020.03.002.CrossRefPubMedPubMedCentral

159.

Guo J, Li L, Wu YJ, Yan Y, Xu XN, Wang SB, et al. Inhibitory effects of Brazilin on the vascular smooth muscle cell proliferation and migration induced by PDGF-BB. Am J Chin Med. 2013;41(6):1283–96. https://doi.org/10.1142/s0192415x13500869.CrossRefPubMed

160.

Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem. 2006;99(6):1553–63. https://doi.org/10.1002/jcb.20993.CrossRefPubMed

161.

Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, Murdoch WJ, et al. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2006;26(1):85–90. https://doi.org/10.1161/01.ATV.0000191635.00744.b6.CrossRefPubMed

162.

Prunotto M, Bacchetta M, Jayaraman S, Galloni M, Van Eys G, Gabbiani G, et al. Cytostatic drugs differentially affect phenotypic features of porcine coronary artery smooth muscle cell populations. FEBS Lett. 2007;581(30):5847–51. https://doi.org/10.1016/j.febslet.2007.11.060.CrossRefPubMed

163.

Wang XS, Fan ZY, Wang T, Xie L, Yu L, Gao ZX, et al. Effects of paclitaxel on proliferation and transition of phenotype in platelet-derived growth factor-BB-induced pulmonary vascular smooth muscle cells. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(7):511–4.PubMed

164.

Lo HM, Tsai YJ, Du WY, Tsou CJ, Wu WB. A naturally occurring carotenoid, lutein, reduces PDGF and H₂O₂ signaling and compromised migration in cultured vascular smooth muscle cells. J Biomed Sci. 2012;19(1):18. https://doi.org/10.1186/1423-0127-19-18.CrossRefPubMedPubMedCentral

165.

Tu L, De Man FS, Girerd B, Huertas A, Chaumais MC, Lecerf F, et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med. 2012;186(7):666–76. https://doi.org/10.1164/rccm.201202-0309OC.CrossRefPubMed

166.

Izikki M, Mercier O, Lecerf F, Guin LL, Hoang E, Dorfmüller P, et al. The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. PLoS ONE. 2013;8(10): e77073. https://doi.org/10.1371/journal.pone.0077073.CrossRefPubMedPubMedCentral

167.

Felix NS, de Mendonça L, Braga CL, da Silva JS, Samary CDS, Vieira JB, et al. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. Br J Pharmacol. 2019;176(23):4462–73. https://doi.org/10.1111/bph.14807.CrossRefPubMedPubMedCentral

168.

Segev A, Aviezer D, Safran M, Gross Z, Yayon A. Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist. Cardiovasc Res. 2002;53(1):232–41. https://doi.org/10.1016/s0008-6363(01)00447-3.CrossRefPubMed

169.

Zheng Y, Ma H, Hu E, Huang Z, Cheng X, Xiong C. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression. J Cardiovasc Pharmacol. 2015;66(5):504–14. https://doi.org/10.1097/fjc.0000000000000302.CrossRefPubMed

170.

Katoh M. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med. 2016;38(1):3–15. https://doi.org/10.3892/ijmm.2016.2620.CrossRefPubMedPubMedCentral

171.

Cottin V. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf. 2017;16(7):857–65. https://doi.org/10.1080/14740338.2017.1338268.CrossRefPubMed

172.

Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes. 2008;57(6):1629–37. https://doi.org/10.2337/db07-0739.CrossRefPubMed

173.

Amin AH, Abd Elmageed ZY, Partyka M, Matrougui K. Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinase. Microvasc Res. 2011;81(1):135–42. https://doi.org/10.1016/j.mvr.2010.11.001.CrossRefPubMed

174.

Wang L, Huang Z, Huang W, Chen X, Shan P, Zhong P, et al. Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress. Sci Rep. 2017;8:45917. https://doi.org/10.1038/srep45917.CrossRefPubMed

175.

Peng LY, Yu M, Yang MX, Liu P, Zhou H, Huang W, et al. Icotinib attenuates monocrotaline-induced pulmonary hypertension by preventing pulmonary arterial smooth muscle cell dysfunction. Am J Hypertens. 2020;33(8):775–83. https://doi.org/10.1093/ajh/hpaa066.CrossRefPubMed

176.

Tang F, Liu M, Zeng O, Tan W, Long J, Liu S, et al. Gefitinib-coated balloon inhibits the excessive hyperplasia of intima after vascular injuries through PI3K/AKT pathway. Technol Health Care. 2019;27(S1):331–43. https://doi.org/10.3233/thc-199031.CrossRefPubMedPubMedCentral

177.

Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69(5):1527–33. https://doi.org/10.1124/mol.105.020172.CrossRefPubMed

178.

Helli B, Gerami H, Kavianpour M, Heybar H, Hosseini SK, Haghighian HK. Curcumin nanomicelle improves lipid profile, stress oxidative factors and inflammatory markers in patients undergoing coronary elective angioplasty; a randomized clinical trial. Endocr Metab Immune Disord Drug Targets. 2021;21(11):2090–8. https://doi.org/10.2174/1871530321666210104145231.CrossRefPubMed

179.

Wang H, Wang Y, Li J, He Z, Boswell SA, Chung M, et al. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med. 2023;21(1):147. https://doi.org/10.1186/s12916-023-02838-2.CrossRefPubMedPubMedCentral

180.

Quagliariello V, Berretta M, Buccolo S, Iovine M, Paccone A, Cavalcanti E, et al. Polydatin reduces cardiotoxicity and enhances the anticancer effects of sunitinib by decreasing pro-oxidative stress, pro-inflammatory cytokines, and NLRP3 inflammasome expression. Front Oncol. 2021;11: 680758. https://doi.org/10.3389/fonc.2021.680758.CrossRefPubMedPubMedCentral

181.

Motokawa T, Ikeda S, Ueno Y, Eguchi M, Minami T, Kawano H, et al. Comparison of dasatinib- and imatinib-related cardiotoxic adverse events in japanese patients with chronic myeloid leukemia and gastrointestinal stromal tumor. Circ Rep. 2022;4(1):1–8. https://doi.org/10.1253/circrep.CR-21-0140.CrossRefPubMed

182.

Morelli MB, Bongiovanni C, Da Pra S, Miano C, Sacchi F, Lauriola M, et al. Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. 2022;9: 847012. https://doi.org/10.3389/fcvm.2022.847012.CrossRefPubMedPubMedCentral

183.

Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12. https://doi.org/10.1200/jco.2007.15.6331.CrossRefPubMed

184.

Bach LA. IGF-binding proteins. J Mol Endocrinol. 2018;61(1):T11-t28. https://doi.org/10.1530/jme-17-0254.CrossRefPubMed

Titel: Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells
verfasst von: Yilin Xiong
Yan Wang
Tao Yang
Yunmei Luo
Shangfu Xu
Lisheng Li
Publikationsdatum: 31.07.2023
Verlag: Springer International Publishing
Erschienen in: American Journal of Cardiovascular Drugs / Ausgabe 5/2023
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-023-00596-3

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis